Syndivia is a research-driven biotechnology company developing new therapeutic modalities for cancers. It is building a pipeline of targeted therapies for solid cancers by leveraging specific targeting of the tumor microenvironment and anatomical hallmarks of solid tumors. The company is led by CEO Sasha Koniev and is based in Strasbourg, France. In October 2020 Syndivia raised €2m in deep-tech financing from Bpifrance. The proceeds will be used to further fund advancement of one of the company’s drug candidates towards the clinic. The financing supports the company’s near-term plan to move that candidate closer to clinical testing.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2020